Polymorphic form of a tachykinin receptor antagonist

U.S. Patent Number: 6432952

Abstract: This invention is concerned with a novel polymorphic forms of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)4-( 5-(dimethyl-amino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)m orpholine hydrochloride which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic forms have advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)4-( 5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)mo rpholine hydrochloride in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.

Inventors: Crocker; Louis (Belle Mead, NJ), Cai; Dongwei (Edison, NJ), Wang; Jiang (Bridgewater, NJ)

Assignee: Merck & Co., Inc. (Rahway, NJ)

Application Number: 09/697,405

Issued: 2002-08-13

Expired: 2006-08-13

Classes: 514/236.2 ; 544/132

Field of search: 544/132 514/236.2

Click the image above to view patent images at uspto.gov within a frame.

Click here for the fulltext page on uspto.gov within a frame.